Houston, Texas. November 12, 2020 – Tvardi Therapeutics (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, was recognized as one of the 10 Most Promising Life Science Companies at the 2020 Texas Life Science Forum. Hosted by BioHouston and the Rice Alliance, the 2020 Texas Life Science Forum is one of the largest life science venture capital conferences in the Southwest. The three-day virtual event highlighted companies throughout the US in various stages of development, with a specific focus on the life science industry in Texas.
This year’s event welcomed over 1000 attendees and 40 investors to explore the latest advances in the industry with presentations from 40 pre-selected companies. Each company’s pitch was judged by venture capitalists attending the forum. Tvardi Therapeutics presented the latest developments in its clinical program evaluating TTI-101 in advanced solid tumors. The preliminary data from the ongoing Phase 1 study indicates TTI-101 is a safe and tolerable drug, with promising clinical activity across a broad range of tumors with particular efficacy in advanced liver cancer.
About Tvardi Therapeutics, Inc.
Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3. STAT3 is a key regulatory protein positioned at the intersection of signaling pathways integral to the survival and immune evasion of cancer cells as well as to the pathogenesis of many inflammatory and fibrotic diseases. STAT3 has long been recognized as a prime target for oncology as it has a dual mechanism in promoting the growth of tumors. Early clinical studies have shown that the company’s lead asset in cancer, TTI-101, is well tolerated and has clinical activity.
To learn more, visit www.tvardi.com.